Search clinical trials for: Injectable cabotegravir

Total 1871 results

Belgian Research on AIDS and HIV Consortium

Not yet recruiting

Use of Long-Acting Injectable Cabotegravir/Rilpivirine for the Treatment of HIV in Belgium

Human Immunodeficiency Virus
Yale University
ViiV Healthcare

Not yet recruiting

Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs

Hiv

United States
University of Zurich
Swiss HIV Cohort Study

Recruiting

Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures

HIV Infections

Switzerland
University Paris 7 - Denis Diderot
Hopital Foch

Not yet recruiting

Patient-Reported Outcomes in Real-life of Cabotegravir and Rilpivirine (PANTER)

Quality of Life
Georgetown University
Johns Hopkins Bloomberg School of Public Health; United States Agency for International... and other collaborators

Recruiting

PathToScale: An Implementation Evaluation

Oral Pre-exposure Prophylaxis (PrEP) | Long-acting Injectable Cabotegravir for PrEP

Malawi
ANRS, Emerging Infectious Diseases

Not yet recruiting

Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France. (CABOPrEP)

Prevention

France
Midway Specialty Care Center

Recruiting

Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP

Hiv

United States
Rhode Island Hospital

Recruiting

Combined Injectable Treatment for HIV and OUD (CHOICE)

Opioid Use Disorder | Human Immunodeficiency Virus

United States
Beth Israel Deaconess Medical Center
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana (Tshireletso)

Breast Feeding | Pre-Exposure Prophylaxis (PrEP)

United States, Botswana
Oregon Health and Science University
ViiV Healthcare

Recruiting

Oregon PrEP at Home Study (OR-PrEP@Home)

HIV/AIDS

United States
FHI 360
United States Agency for International Development (USAID); Jhpiego; Wits Reproductive... and other collaborators

Recruiting

The CATALYST Study

HIV Prevention

Kenya, Lesotho, South Africa, Uganda, Zimbabwe
Kelley-Ross & Associates, Inc.

Not yet recruiting

Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting. (IDCaPP)

HIV Infections

United States
Pontificia Universidad Catolica de Chile
ViiV Healthcare

Not yet recruiting

Switch From Oral Therapy to Long-acting Injectable Cabotegravir + Rilpivirine (CABO-LA)

Quality of Life | Patient Satisfaction | Patient Preference | Acceptability of Health Care

Chile
Alexis Roth
University of Miami; Beth Israel Deaconess Medical Center; University of Michigan and other collaborators

Recruiting

Optimizing CAB-LA as PrEP for Women Who Inject Drugs

HIV Infections | Opioid Use | Trauma, Psychological

United States
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Satisfaction of HIV-infected Patients Treated With Cabotegravir-rilpivirine Injectable Dual Therapy (CABORI)

HIV Infections
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age

HIV-1-infection

United States, Brazil, South Africa, Uganda, Botswana, Thailand
Evandro Chagas National Institute of Infectious...
Beatriz Grinsztejn; Thiago Torres; Valdilea Gonçalves; Brenda Hoagland

Not yet recruiting

The Implementation of Pre-exposure Prophylaxis of Injectable Cabotegravir (ImPrepCab)

HIV Infections

Brazil
ViiV Healthcare

Recruiting

A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories (EBONI)

HIV Infections

United States
University of Alabama at Birmingham
National Institute of Allergy and Infectious Diseases (NIAID); Indiana University and other collaborators

Recruiting

Kuwa Free! - Live Free!

HIV Infections | Contraception | Drug-drug Interaction

Kenya
National Institute of Allergy and Infectious Diseases...
ViiV Healthcare

Recruiting

The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

HIV Infections

United States, Puerto Rico
Emory University
National Institute of Mental Health (NIMH)

Active, not recruiting

Parrying the Pitfalls of PrEP: Project PEACH

HIV | STI

United States
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

HIV Infections | Infection, Human Immunodeficiency Virus

Germany, Spain, France, United States, Canada
ViiV Healthcare
GlaxoSmithKline; PPD

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy (VOLITION)

HIV Infections

United States, France, Germany, Canada, Spain, Italy, Argentina, Chile, Puerto Rico
ViiV Healthcare
Janssen, LP

Completed

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed (SOLAR)

HIV Infections

United States, Netherlands, Germany, Canada, Australia, Belgium, France, Spain, Ireland, Italy, United Kingdom, Austria, Japan, Switzerland
National Institute of Allergy and Infectious Diseases...
ViiV Healthcare

Completed

Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
ViiV Healthcare

Active, not recruiting

More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (MOCHA)

HIV Infections

Thailand, United States, Botswana, Uganda, South Africa
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants

HIV Infections

United States
ViiV Healthcare
Janssen Pharmaceuticals

Completed

A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries

HIV Infections

Germany, Netherlands, France, Belgium, Spain
National Institute of Allergy and Infectious Diseases...
Gilead Sciences; ViiV Healthcare

Active, not recruiting

Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

HIV Infections

Brazil, United States, South Africa, Peru, Thailand, Argentina, Vietnam
University of California, San Francisco
National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute... and other collaborators

Active, not recruiting

SEARCH CAB LA Dynamic Choice HIV Prevention Study Extension

HIV

Kenya, Uganda
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Active, not recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

HIV Infections

United States, Germany, Netherlands, Spain, France, Canada, United Kingdom, Italy, South Africa, Russian Federation, Japan
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Active, not recruiting

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

HIV Infections | Infection, Human Immunodeficiency Virus

Germany, Spain, France, United States, Canada, Australia, Korea, Republic of, Italy, South Africa, Russian Federation, Argentina, Mexico, Sweden
ViiV Healthcare

Active, not recruiting

A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States (PILLAR)

HIV Infections

United States
ViiV Healthcare
Janssen Research and Development

Active, not recruiting

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults (ATLAS-2M)

HIV Infections

United States, Germany, Spain, France, Canada, Korea, Republic of, Italy, South Africa, Australia, Russian Federation, Mexico, Sweden, Argentina
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study

Human Immunodeficiency Virus Type 1 (HIV-1)

United States, Spain, Canada, United Kingdom, South Africa, Japan
University of Witwatersrand, South Africa
Bill and Melinda Gates Foundation; ViiV Healthcare

Active, not recruiting

Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa (AXIS)

HIV Infections

South Africa
University of California, San Francisco
Texas A&M University; ViiV Healthcare; Auburn University; Nova Southeastern University

Completed

Preparing for Pharmacy-based Delivery of Long-acting Injectable Antiretroviral Therapy (LAI-ART)

Hiv

United States
Boston Medical Center
ViiV Healthcare

Completed

Improving Treatment and Retention Adherence in Nontraditional Settings (I-TRAINS)

HIV Infections

United States
ViiV Healthcare
Janssen Research and Development

Completed

A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants

Human Immunodeficiency Virus Type 1 (HIV-1)

Germany, Spain, United States, Italy, Canada, Argentina, Sweden
ViiV Healthcare

Completed

Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Active, not recruiting

Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

HIV Infections

Zimbabwe, South Africa, Botswana, Kenya, Malawi, Uganda, Swaziland
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults

HIV Infections

United States, Malawi, Brazil, South Africa
Centre for the AIDS Programme of Research in South...
ViiV Healthcare

Withdrawn

Safety and Acceptability of Cabotegravir in HIV Uninfected Women in KwaZulu-Natal, South Africa (CAPRISA014)

Human Immunodeficiency Virus

South Africa
ViiV Healthcare
GlaxoSmithKline

Completed

A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects

Infections, Human Immunodeficiency Virus and Herpesviridae
Fujian Cancer Hospital
Zhangzhou Municipal Hospital of Fujian Province

Recruiting

Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer

Cervical Cancer Recurrent

China
Changchun GeneScience Pharmaceutical Co., Ltd.

Recruiting

A Bioequivalence Study of Two Different Dosage Form of Genakumab

Gouty Arthritis (GA)

China
Technical University of Munich
Universitaire Ziekenhuizen KU Leuven; Helmholtz Zentrum München; Skane University... and other collaborators

Recruiting

Anti-viral Action Against Type 1 Diabetes Autoimmunity

Diabetes Mellitus, Type 1

Belgium, Germany, Sweden
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Not yet recruiting

A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps

Chronic Rhinosinusitis With Nasal Polyps

China
University of Nebraska
ViiV Healthcare

Not yet recruiting

IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas (IM-CAPABLE)

HIV

United States
University of California, San Diego
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Not yet recruiting

Androgen Effects on the Reproductive Neuroendocrine Axis

Reproductive Issues | Transgenderism

United States

Search clinical trials for: Injectable cabotegravir

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations